Best Value Stocks To Invest In Right Now

Epoch Investment Partners Inc. boosted its position in shares of Republic Services (NYSE:RSG) by 21.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 318,852 shares of the business services provider’s stock after acquiring an additional 55,925 shares during the period. Epoch Investment Partners Inc.’s holdings in Republic Services were worth $21,118,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of RSG. SeaCrest Wealth Management LLC purchased a new stake in Republic Services during the fourth quarter valued at approximately $121,000. Signaturefd LLC purchased a new stake in Republic Services during the first quarter valued at approximately $149,000. Tower Research Capital LLC TRC lifted its position in Republic Services by 1,070.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,937 shares of the business services provider’s stock valued at $199,000 after acquiring an additional 2,686 shares during the last quarter. Focused Wealth Management Inc purchased a new stake in Republic Services during the fourth quarter valued at approximately $199,000. Finally, Schroder Investment Management Group lifted its position in Republic Services by 41.4% during the fourth quarter. Schroder Investment Management Group now owns 3,104 shares of the business services provider’s stock valued at $210,000 after acquiring an additional 909 shares during the last quarter. 60.11% of the stock is owned by institutional investors.

Best Value Stocks To Invest In Right Now: Northgate Minerals Corporation(NXG)

Advisors’ Opinion:

  • [By Shane Hupp]

    Shares of NEX Group PLC (LON:NXG) have been given an average rating of “Hold” by the nine ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 696 ($9.21).

Best Value Stocks To Invest In Right Now: Jazz Pharmaceuticals Inc.(JAZZ)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Marriott International, Inc. (NASDAQ: MAR) is projected to post quarterly earnings at $1.22 per share on revenue of $5.72 billion.
    Electronic Arts Inc. (NASDAQ: EA) is estimated to post quarterly earnings at $1.04 per share on revenue of $5.68 billion.
    The Walt Disney Company (NYSE: DIS) is projected to post quarterly earnings at $1.68 per share on revenue of $14.05 billion.
    Papa John's International, Inc. (NASDAQ: PZZA) is expected to post quarterly earnings at $0.62 per share on revenue of $441.73 million.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post quarterly earnings at $2.77 per share on revenue of $434.87 million.
    Sun Life Financial Inc. (NYSE: SLF) is estimated to post quarterly earnings at $0.89 per share on revenue of $6.38 billion.
    LATAM Airlines Group S.A. (NYSE: LTM) is expected to post quarterly earnings at $0.16 per share on revenue of $2.70 billion.
    Liberty Global plc (NASDAQ: LBTYA) is projected to post quarterly earnings at $0.02 per share on revenue of $4.05 billion.
    TripAdvisor, Inc. (NASDAQ: TRIP) is expected to post quarterly earnings at $0.16 per share on revenue of $362.11 million.
    The Wendy's Company (NASDAQ: WEN) is projected to post quarterly earnings at $0.1 per share on revenue of $379.98 million.
    A-Mark Precious Metals, Inc. (NASDAQ: AMRK) is expected to post quarterly earnings at $0.06 per share on revenue of $1.69 billion.
    Monster Beverage Corporation (NASDAQ: MNST) is estimated to post quarterly earnings at $0.4 per share on revenue of $849.38 million.
    Convergys Corporation (NYSE: CVG) is expected to post quarterly earnings at $0.4 per share on revenue of $670.10 million.
    ScanSource, Inc. (NASDAQ: SCSC) is projected to post quarterly earnings at $0.7 per share on revenue of $875.91 million.
    KAR Auction Services, Inc. (NYSE: KAR) is expected to post quarterly earnings at $0.76 per share on revenue of $923.13

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Jazz Pharmaceuticals’ sleep disorder drug, Xyrem, has witnessed improved volume trends so far in 2018, sales were  disappointing in 2017. Notably, Xyrem generates majority of sales, and consequently any setback is likely to hamper Jazz’s top-line. Moreover, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity. These supply challenges are expected to continue in 2019. Meanwhile, its newest drug Vyxeos performed below expectations leading Jazz to lower its full-year outlook. However, management seems confident that Xyrem will continue to generate volume growth in future quarters. The company’s lead pipeline candidate solriamfetol complements its existing sleep disorder portfolio. Estimates movement remianed mixed ahead of Q4 earnings. Jazz has a positive record of earnings surprises in the recent quarters.”

  • [By Max Byerly]

    Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

  • [By Logan Wallace]

    Swiss National Bank trimmed its holdings in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 13.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,000 shares of the specialty pharmaceutical company’s stock after selling 29,100 shares during the quarter. Swiss National Bank owned 0.32% of Jazz Pharmaceuticals worth $28,990,000 at the end of the most recent reporting period.

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    So which biotechnology stocks do we think are smart buys right now? We asked these three Motley Fool investors — all healthcare experts — to weigh in, and they picked Vertex Pharmaceuticals (NASDAQ:VRTX), Jazz Pharmaceuticals (NASDAQ:JAZZ), and Neurocrine Biosciences (NASDAQ:NBIX).

Best Value Stocks To Invest In Right Now: RMG Networks Holding Corporation(RMGN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Media coverage about RMG Networks (NASDAQ:RMGN) has trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RMG Networks earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the business services provider an impact score of 45.2069122997124 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Best Value Stocks To Invest In Right Now: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Media headlines about Vermillion (NASDAQ:VRML) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vermillion earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.6924212135165 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Joseph Griffin]

    Vermillion (NASDAQ: VRML) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

  • [By Benzinga News Desk]

    Shari Redstone is one “disloyal” media heiress, according to CBS (NYSE: CBS): Link

    ECONOMIC DATA
    US Initial Jobless Claims for May 18 234.0K vs 220.0K Est; Prior 222.0K. US Continuing Claims for May 11 1.74M vs 1.75M Est; Prior 1.71M
    Existing home sales report for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    Atlanta Fed President Raphael Bostic will speak at 10:35 a.m. ET.
    The Treasury is set to auction 7-year notes at 1:00 p.m. ET.
    The Kansas City Fed manufacturing index for May will be released at 11:00 a.m. ET.
    Philadelphia Federal Reserve Bank President Patrick Harker is set to speak at 2:00 p.m. ET.
    Data on money supply for the latest week will be released at 4:30 p.m. ET.
    ANALYST RATINGS
    UBS upgrades Deere (NYSE: DE) from Neutral to Buy
    Wells Fargo upgrades Oceaneering (NYSE: OII) from Market Perform to Outperform
    Canaccord downgrades Vermillion (NASDAQ: VRML) from Buy to Hold
    Wedbush downgrades Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

Best Value Stocks To Invest In Right Now: EMCORE Corporation(EMKR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    EMCORE Co. (NASDAQ:EMKR) traded up 8% during mid-day trading on Monday . The stock traded as high as $5.10 and last traded at $5.26. 11,341 shares changed hands during trading, a decline of 95% from the average session volume of 216,974 shares. The stock had previously closed at $4.87.

  • [By Stephan Byrd]

    EMCORE Co. (NASDAQ:EMKR) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.00.

  • [By Max Byerly]

    News stories about EMCORE (NASDAQ:EMKR) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EMCORE earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the semiconductor company an impact score of 45.6118508960632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Logan Wallace]

    News articles about EMCORE (NASDAQ:EMKR) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EMCORE earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the semiconductor company an impact score of 46.9972095148836 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is the most shorted stock on the NASDAQ with short interest of 62.65% according to Highshortnterest.com.

Best Value Stocks To Invest In Right Now: Ecolab Inc.(ECL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Ecolab Inc. (NYSE:ECL) – Jefferies Financial Group dropped their Q4 2018 EPS estimates for Ecolab in a report released on Tuesday, July 31st. Jefferies Financial Group analyst L. Alexander now anticipates that the basic materials company will post earnings per share of $1.73 for the quarter, down from their prior forecast of $1.74.

  • [By Scott Levine]

    Here are three starkly different opportunities — Aqua America (NYSE:WTR), Franco-Nevada Corp. (NYSE:FNV), and Ecolab (NYSE:ECL) — that could help investors avoid tossing and turning all night.

  • [By Max Byerly]

    In other news, Chairman Douglas M. Baker, Jr. sold 40,025 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $160.20, for a total transaction of $6,412,005.00. Following the completion of the sale, the chairman now directly owns 558,017 shares in the company, valued at $89,394,323.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Leslie S. Biller sold 2,811 shares of the stock in a transaction on Friday, November 30th. The stock was sold at an average price of $160.40, for a total transaction of $450,884.40. Following the sale, the director now owns 57,842 shares of the company’s stock, valued at $9,277,856.80. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

    ILLEGAL ACTIVITY NOTICE: “Ecolab (ECL) Updates Q4 Earnings Guidance” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at www.tickerreport.com/banking-finance/4125845/ecolab-ecl-updates-q4-earnings-guidance.html.

    About Ecolab

Leave a Reply

Your email address will not be published. Required fields are marked *